Vaduz Liechtenstein Charlevoix Sovereign Strategic Investment Fund
Additional shared vehicles: SV Life Sciences Fund VI, L.P. (2025 Vintage) · SV Biotech Crossover Opportunities Fund, L.P. (2025 Vintage)
$12.8B Total AUM · Institutional LP profile covering 17 historical fund disclosure records ($757.2M parsed USD across disclosed rows) across disclosed strategy exposure in Buyout, Venture Capital, Private Credit, Distressed / Special Situations, Secondaries (investment geography mandates are evaluated separately from LP headquarters). 5 complete primary source trails are open below without registration.
Showing 5 open preview records out of 17 total tracked records (+12 gated pilot rows). Click Inspect Source on any row to view field-level substantiation, table headers/units, and archived page excerpts without login.
| Disclosed Fund / Vehicle | Strategy | Fund Vintage | Advised Vehicle GAV | Disclosed Performance | Primary Source Trail |
|---|---|---|---|---|---|
| SV7 Impact Medicine Fund, L.P.Adviser 7.B Vehicle | Buyout | 2025 |
$56.5M
Adviser-managed fund GAV · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · SEC Form ADV 7.B |
| SV Life Sciences Fund VI, L.P.Adviser 7.B Vehicle | Buyout | 2025 |
$50.0M
Adviser-managed fund GAV · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · SEC Form ADV 7.B |
| SV Biotech Crossover Opportunities Fund, L.P.Adviser 7.B Vehicle | Buyout | 2025 |
$12.0M
Adviser-managed fund GAV · As of March 2026
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · SEC Form ADV 7.B |
| OrbiMed Royalty Credit Opps VAdviser 7.B Vehicle | Private Credit | 2025 |
$74.0M
Adviser-managed fund GAV · As of December 2025
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · SEC Form ADV 7.B |
| Khosla Ventures Opportunity III. L.P.Adviser 7.B Vehicle | Venture Capital | 2025 |
$66.2M
Adviser-managed fund GAV · As of December 2025
|
Active 2025–2026 Drawdown · J-Curve / Initial Deployment Period | Inspect Source · SEC Form ADV 7.B |
Tracked separately from historical commitments: active RFPs/searches, board pacing plans, leadership/CIO updates, and retained gatekeeper consultants.
Pugh Capital Management, Inc. (OCIO / Wealth RIA, $12.8B AUM): Disclosed FY2025-2026 Private Markets Pacing & Allocation Update (PE Target 19.0% vs. 18.2% Actual; $102.5M Unallocated Target Bandwidth). SEC Form ADV (801-39138, CRD #111765) verified $12.81B discretionary AUM (Item 7.B Schedule D Private Feeder Funds); active 2026 allocations across Fund I-IV Buyout, Growth/VC & Private Credit ($5M-$20M checks). Gatekeeper / Intake Conduit: Internal Investment Office.
Forward-looking board pacing or target-allocation policy update · Recorded 2025-05-13
Board-Approved Pacing Plans, Active RFPs & Target-vs-Actual Allocation Gap
Join waitlist for pacing dossier →
Retained Private Markets Advisors & Emerging-Manager Search Conduits
Join waitlist for consultant map →
CIO, Private Markets Officers & Official Pitch Intake Guidance
Join waitlist for team directory →
You are viewing 5 open public preview records (out of 17 total tracked records for Pugh Capital Management, Inc.) with zero-registration primary source trails. Join the early-access waitlist to request pilot access:
Enter your firm email to request pilot onboarding for Pugh Capital Management, Inc. and our interactive GP workspace.
Thank you for joining the Prilago early-access waitlist! We will reach out with pilot access details for your firm.
Pugh Capital Management, Inc. is categorized under OCIO / Wealth RIA (Regional Roadshow Hub: Seattle, WA; Headquarters: Seattle, WA). Across 17 historical disclosure records tracked on Prilago ($757.2M total parsed USD across disclosed rows), the median disclosed amount is $50.0M (range: $8.0M to $89.6M).
Pugh Capital Management, Inc. has disclosed records across Buyout, Venture Capital, Private Credit, Distressed / Special Situations, Secondaries. Open preview records include SV7 Impact Medicine Fund, L.P. (2025 Vintage), SV Life Sciences Fund VI, L.P. (2025 Vintage), SV Biotech Crossover Opportunities Fund, L.P. (2025 Vintage), OrbiMed Royalty Credit Opps V (2025 Vintage).
Records for Pugh Capital Management, Inc. cite primary public disclosures (SEC Form ADV 7.B), and visitors can inspect 5 open source trails on this profile without registration. Each source trail displays field-level substantiation status, distinguishing exact commitment schedules from carrying-value or fee tables. Forward-looking active searches, RFPs, pacing plans, and governance updates are separated from historical disclosures.
General Partners can join the early-access waitlist on https://prilago.com/lp/pugh-capital-management-inc or test fund suitability in the interactive read-only demo at https://prilago.com/demo.
In Prilago's bilateral commitment graph, Pugh Capital Management, Inc. shares resolved underlying fund vehicles with 549 institutional LPs across 17 shared vehicles (shared fund exposure represents a potential introduction path and does not prove LPAC seat overlap or personal acquaintance). Top shared-fund peers include Vaduz Liechtenstein Charlevoix Sovereign Strategic Investment Fund (5 shared vehicles, e.g. SV7 Impact Medicine Fund, L.P. (2025 Vintage)), Delmarva Fauquier Livingston Multi-Family Office Private Capital Platform (5 shared vehicles, e.g. SV Life Sciences Fund VI, L.P. (2025 Vintage)), Fairfield County Hopewell Pendleton Institutional Outsourced CIO & Wealth Advisory (5 shared vehicles, e.g. SV Biotech Crossover Opportunities Fund, L.P. (2025 Vintage)).